{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:49:30Z","timestamp":1775810970212,"version":"3.50.1"},"reference-count":133,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Since the introduction of first-generation proteasome inhibitors and immunomodulatory agents, the multiple myeloma (MM) treatment landscape has undergone a remarkable development. Most recently, immunotherapeutic strategies targeting the B cell maturation antigen (BCMA) entered the clinical stage providing access to highly anticipated novel treatment strategies. At present, numerous different approaches investigate BCMA as an effective multi-modal target. Currently, BCMA-directed antibody\u2013drug conjugates, bispecific and trispecific antibodies, autologous and allogeneic CAR-T cell as well as CAR-NK cell constructs are either approved or in different stages of clinical and preclinical development for the treatment of MM. This armamentarium of treatment choices raises several challenges for clinical decision making, particularly in the absence of head-to-head comparisons. In this review, we provide a comprehensive overview of BCMA-targeting therapeutics, deliver latest updates on clinical trial data, and focus on potential patient selection criteria for different BCMA-targeting immunotherapeutic strategies.<\/jats:p>","DOI":"10.3390\/cancers13184701","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T07:52:14Z","timestamp":1632124334000},"page":"4701","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Agony of Choice\u2014Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond"],"prefix":"10.3390","volume":"13","author":[{"given":"Irene","family":"Strassl","sequence":"first","affiliation":[{"name":"Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, 4020 Linz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-9715","authenticated-orcid":false,"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Klinik Ottakring, 1160 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-1309","authenticated-orcid":false,"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Rudzki","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermine","family":"Agis","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"K\u00fcnz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"M\u00fcser","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Klinik Ottakring, 1160 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria"},{"name":"Oncotyrol, Center for Personalized Cancer Medicine, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[{"name":"Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, 4020 Linz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Neumeister","sequence":"additional","affiliation":[{"name":"Division of Hematology, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Theresa","family":"Krauth","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,19]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2021, July 11). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With \u22653 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple mye-loma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells","volume":"199","author":"Raman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR-T-cell therapy for multiple myeloma: State of the art and prospects","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for target-ing and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refrac-tory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric an-tigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","first-page":"297","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Chabannon","year":"2019","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2013assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","first-page":"26","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results","volume":"39","author":"Larry","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134319","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study","volume":"136","author":"Raje","year":"2020","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhao, W.-H., Liu, J., Wang, B.-Y., Chen, Y.-X., Cao, X.-M., Yang, Y., Zhang, Y.-L., Wang, F.-X., Zhang, P.-Y., and Lei, B. (2018). A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol., 11.","DOI":"10.1186\/s13045-018-0681-6"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"P314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTI-TUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-136360","article-title":"Cytokine Release Syndrome in Patients with Relapsed\/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b\/2 CARTITUDE-1 Study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1","volume":"39","author":"Usmani","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Agha, M.E., Cohen, A.D., Madduri, D., Cohen, Y.C., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., and Scheid, C. (2021). CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.8013"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-140641","article-title":"Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Mailankody","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mailankody, S., Jakubowiak, A.J., Htut, M., Costa, L.J., Lee, K., Ganguly, S., Kaufman, J.L., Siegel, D.S.D., Bensinger, W., and Cota, M. (2020). Orvacabtagene autoleucel (orva-cel), a B-cell matu-ration antigen (BCMA)-directed CAR-T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Update of the phase 1\/2 EVOLVE study (NCT03430011). J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8504"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-139802","article-title":"Results from Lummicar-2: A Phase 1b\/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR-T Cells (CT053) in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-138734","article-title":"An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma","volume":"136","author":"An","year":"2020","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Caraccio, C., Krishna, S., Phillips, D., and Sch\u00fcrch, C.M. (2020). Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00501"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.20.00223","article-title":"BiTEing the Tumor","volume":"38","author":"Kumar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.18632\/oncotarget.27792","article-title":"T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sanchez, L., Dardac, A., Madduri, D., Richard, S., and Richter, J. (2021). B-cell maturation antigen (BCMA) in multiple myeloma: The new frontier of targeted therapies. Ther. Adv. Hematol., 12.","DOI":"10.1177\/2040620721989585"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhou, X., Einsele, H., and Danhof, S. (2020). Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072166"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Geis, M., Nowotny, B., Bohn, M.-D., Kouhestani, D., Einsele, H., Bumm, T., and Stuhler, G. (2021). Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Commun. Biol., 4.","DOI":"10.1038\/s42003-020-01558-0"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma","volume":"18","author":"Panowski","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging anti-body demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR-T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific anti-body against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"mAbs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (bispecific T-cell engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Usmani, S.Z., Mateos, M.-V., Nahi, H., Krishnan, A.Y., Van De Donk, N.W., Miguel, J.S., Oriol, A., Rosi\u00f1ol, L., Chari, A., and Adams, H. (2020). Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (R\/R MM). J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.100"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Garfall, A.L., Usmani, S.Z., Mateos, M.-V., Nahi, H., Van De Donk, N.W., San-Miguel, J.F., Rocafiguera, A.O., Rosinol, L., Chari, A., and Bhutani, M. (2020). Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) \u00d7 CD3 Bispecific Antibody, in Relapsed and\/or Refractory Multiple Myeloma (RRMM). Blood, 136.","DOI":"10.1182\/blood-2020-138831"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Krishnan, A.Y., Garfall, A.L., Mateos, M.-V., van de Donk, N.W.C.J., Nahi, H., San-Miguel, J.F., Oriol, A., Rosi\u00f1ol, L., Chari, A., and Bhutani, M. (2021). Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM). J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.8007"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-139893","article-title":"Initial Results of a Phase I Study of TNB-383B, a BCMA \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Bahlis, N.J., Raje, N.S., Costello, C., Dholaria, B.R., Solh, M.M., Levy, M.Y., Tomasson, M.H., Dube, H., Liu, F., and Liao, K.H. (2021). Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.8006"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-143470","article-title":"Outcome of BCMA Bite (AMG420) Therapy in Relapse and Refractory Multiple Myeloma (RRMM) Patients","volume":"136","author":"Topp","year":"2020","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical Activity of JNJ-7957, a Novel BCMA\u00d7CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Raje, N., Jakubowiak, A., Gasparetto, C., Cornell, R., Krupka, H., Navarro, D., Forgie, A.J., Udata, C., Basu, C., and Chou, J. (2019). Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood, 134.","DOI":"10.1182\/blood-2019-121805"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Cho, S.-F., Anderson, K.C., and Tai, Y.-T. (2018). Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01821"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Schade, H., Madan, S., Medvedova, E., Nath, R., Knapp, L., Lemon, B., and Sun, L.L. (2020). HPN217-3001: A Phase 1\/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed\/Refractory Multiple Myeloma. Blood, 136.","DOI":"10.1182\/blood-2020-136012"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) \u2013Positive Breast Cancer After Prior HER2-Directed Therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical assessment of an antibody\u2013PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells","volume":"33","author":"Kinneer","year":"2018","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Singh, R.K., Jones, R.J., Hong, S., Shirazi, F., Wang, H., Kuiatse, I., Pahl, A., and Orlowski, R.Z. (2018). HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to \u03b1-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p. Blood, 132.","DOI":"10.1182\/blood-2018-99-118412"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Trudel, S., Lendvai, N., Popat, R., Voorhees, P.M., Reeves, B., Libby, E.N., Richardson, P.G., Hoos, A., Gupta, I., and Bragulat, V. (2019). Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study. Blood Cancer J., 9.","DOI":"10.1038\/s41408-019-0196-6"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1200\/JCO.2020.38.15_suppl.8536","article-title":"Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and\/or intolerant to anti-CD38 monoclonal antibodies (mAbs)","volume":"38","author":"Lonial","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Lonial, S., Lee, H.C., Badros, A., Trudel, S., Nooka, A., Chari, A., Abdallah, A.-O., Callander, N.S., Sborov, D., and Suvannasankha, A. (2020). DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) \u2013 1-Year Outcomes By Prior Therapies. Blood, 136.","DOI":"10.1182\/blood-2020-140078"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Cohen, A.D., Trudel, S., Lonial, S., Libby, E.N., Lee, H.C., Besemer, B., Facon, T., Nooka, A.K., Callander, N.S., and Chari, A. (2020). DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8541"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-140078","article-title":"Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Lonial","year":"2020","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Lee, H.C., Abdallah, A.-O., Cohen, A.D., Kapoor, P., Voorhees, P.M., Hoos, A., Wang, K., Baron, J., and Piontek, T. (2020). Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: Analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J., 10.","DOI":"10.1038\/s41408-020-00369-0"},{"key":"ref_87","first-page":"25","article-title":"Part 1 Results of a Dose Finding Study of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Trudel, S., Davis, R., Lewis, N.M., Bakshi, K.K., Chopra, B., De Oca, R.M., Ferron-Brady, G., Eliason, L., Kremer, B.E., and Gupta, I. (2020). DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood, 136.","DOI":"10.1182\/blood-2020-139785"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-139332","article-title":"DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib\/Dexamethasone (BorDex) in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-139181","article-title":"DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Rifkin","year":"2020","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design","volume":"17","author":"Nooka","year":"2021","journal-title":"Futur. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Strassz, A., Raab, M.S., Orlowski, M.R.Z., Kulke, M., Schiedner, G., and Pahl, A. (2020). A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma. Blood, 136.","DOI":"10.1182\/blood-2020-142285"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a Target of Antibody\u2013Drug Conjugates for the Treatment of Multiple Myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal Epitope Facilitates Efficient T Cell Synpase Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Stewart, A.K., Krishnan, A.Y., Singhal, S., Boccia, R.V., Patel, M.R., Niesvizky, R., Chanan-Khan, A.A., Ailawadhi, S., Brumm, J., and Mundt, K.E. (2019). Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J., 9.","DOI":"10.1038\/s41408-019-0178-8"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial Clinical Activity and Safety of BFCR4350A, a FcRH5\/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG Family Member, GPRC5D, Is Associated with Hard-Keratinized Structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Smith, E.L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T.J., Ng, K.Y., Ghoddusi, M., Purdon, T.J., and Wang, X. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med., 11.","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR-T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma","volume":"1","author":"Staehr","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-133873","article-title":"A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Recetor Family C Group 5 Member D (GPRC5D) \u00d7 CD3 Bispecific Antibody, in Patients with Relapsed and\/or Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Chari","year":"2020","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Berdeja, J.G., Krishnan, A.Y., Oriol, A., Van De Donk, N.W.C.J., Rodr\u00edguez-Otero, P., Askari, E., Mateos, M.-V., Minnema, M.C., Costa, L.J., and Verona, R. (2021). Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM). J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.8008"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"His","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1078-0432.CCR-19-1431","article-title":"First-in-Human Phase I Study of ABBV-838, an Anti-body-Drug Conjugate Targeting SLAMF7\/CS1 in Patients with Relapsed and Refractory Multiple Myeloma","volume":"26","author":"Vij","year":"2020","journal-title":"Clin. cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Radocha, J., van de Donk, N., and Weisel, K. (2021). Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13071571"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136928","article-title":"TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells","volume":"136","author":"Bruins","year":"2020","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.1200\/JCO.2021.39.15_suppl.8044","article-title":"ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma","volume":"39","author":"Doucey","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Li, C., Mei, H., Hu, Y., Guo, T., Liu, L., Jiang, H., Tang, L., Wu, Y.H., Ai, L., and Deng, L. (2019). A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed\/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial. Blood, 134.","DOI":"10.1182\/blood-2019-130340"},{"key":"ref_116","first-page":"25","article-title":"Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2020","journal-title":"Cancer Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR-T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_122","first-page":"28","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen recep-tor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"Transplant Cell Ther."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Yu, B., Jiang, T., and Liu, D. (2020). BCMA-targeted immunotherapy for multiple myeloma. J. Hematol. Oncol., 13.","DOI":"10.1186\/s13045-020-00962-7"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Timmers, M., Roex, G., Wang, Y., Campillo-Davo, D., Van Tendeloo, V.F.I., Chu, Y., Berneman, Z., Luo, F., Van Acker, H.H., and Anguille, S. (2019). Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01613"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Yu, B., and Liu, D. (2019). Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J. Hematol. Oncol., 12.","DOI":"10.1186\/s13045-019-0786-6"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/leu.2015.341","article-title":"Gene signature combinations improve prognos-tic stratification of multiple myeloma patients","volume":"30","author":"Chng","year":"2016","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.20.00461","article-title":"Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group","volume":"38","author":"Samur","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2020.38.15_suppl.8505","article-title":"Update of CARTITUDE-1: A phase Ib\/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma","volume":"38","author":"Berdeja","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Munshi, N.C., Larry, D., Anderson, J., Shah, N., Jagannath, S., Berdeja, J.G., Lonial, S., Raje, N.S., Siegel, D.S.D., and Lin, Y. (2020). Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR-T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8503"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-136383","article-title":"Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b\/2 Study of Ciltacabtagene Autoleucel in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-136665","article-title":"Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial","volume":"136","author":"Shah","year":"2020","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4701\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:22Z","timestamp":1760166142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,19]]},"references-count":133,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13184701"],"URL":"https:\/\/doi.org\/10.3390\/cancers13184701","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,19]]}}}